CLPT insider plans sale of 26,463 shares via Morgan Stanley on 10/10/2025

Rhea-AI Filing Summary

ClearPoint Neuro, Inc. filed a Form 144 reporting a proposed sale of 26,463 common shares through Morgan Stanley Smith Barney LLC on 10/10/2025. The filing lists an aggregate market value of $766,368.48 and shows 28,427,417 shares outstanding. The shares to be sold were acquired in two events: 5,599 shares via an Employee Stock Purchase Plan (12/30/2021) paid in cash, and 20,864 shares from a previously vested RSA (07/09/2022). No sales by the seller in the past three months are reported. The notice includes the standard representation that the seller has no undisclosed material information.

Positive

• Shares originate from compensation plans (ESPP and vested RSA), indicating liquidity of earned equity rather than new issuance
• No reported sales in the prior 3 months, suggesting this filing is not part of repeated short-term selling

Negative

• Proposed sale increases available supply of the issuer's common stock on 10/10/2025
• Insider selling may be perceived negatively by some investors despite originating from compensation

Insights

Equity Compensation Analyst

Insider sale is routine compensation liquidity from ESPP and vested RSA.

The filing shows the seller intends to use a broker to sell 26,463 common shares acquired through an Employee Stock Purchase Plan and a previously vested restricted stock award. The use of an institutional broker and the split acquisition dates (12/30/2021 and 07/09/2022) are consistent with routine post-vesting liquidity events rather than newly issued shares.

Primary dependencies include market execution on 10/10/2025 and the absence of other recent sales (the form reports "Nothing to Report" for the past 3 months). Watch settlement and any subsequent filings disclosing completed sales within days after the approximate sale date.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/10/2025 - 04:16 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	26463	766368.48	28427417	10/10/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	12/30/2021	Employee Stock Purchase Plan	Issuer			5599	12/30/2021	Cash
Common	07/09/2022	Previously vested RSA	Issuer			20864	07/09/2022	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed by ClearPoint Neuro (CLPT) report?

The form reports a proposed sale of 26,463 common shares via Morgan Stanley Smith Barney LLC with an aggregate market value of $766,368.48 and an approximate sale date of 10/10/2025.

How were the shares being sold by CLPT acquired?

The filing shows 5,599 shares acquired under an Employee Stock Purchase Plan on 12/30/2021 (paid in cash) and 20,864 shares from a previously vested RSA on 07/09/2022.

Does the filer report other sales in the past three months for CLPT?

No. The filing states "Nothing to Report" for securities sold during the past three months by the person for whose account the securities are to be sold.

What is the reported number of shares outstanding for ClearPoint Neuro?

The filing lists 28,427,417 shares outstanding.

Which broker is handling the proposed sale for CLPT?

The broker named is Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY 10004.